funfun

Five Companies Worth Researching This Weekend

Additionally on DuPont's bleak prospects, DuPont Senior Management, specifically DuPont Executive Vice President Mark Vergnano, admitted to private investors less than a month ago, Oct. 6, 2009, that DuPont would not match its noticeably weak earnings of 2008, or diluted earnings per share of $2.20, until the earliest well into the next decade, 2012! This tells me the intervening years will show sick results.

...funfun..

Five Companies Worth Researching This Weekend

Pressure on DuPont's rich annual dividend of $1.64 per share will be intensifying as DuPont faces a looming BIG BLACK HOLE of vanishing Pharma earnings! The sure and certain expiration of the patents protecting DuPont Cozaar® and Hyzaar® will begin to blowtorch more than $1 billion of Pharma PTOI yearly. These two drugs are the only key assets remaining in DuPont's fading and phased-out Pharma "growth platform".

For perspective, in the first nine months of this year, 2009, Pharma accounted for circa one-third of total DuPont PTOI! DuPont's customarily secretive Management to date has said very little publicly about this BIG BLACK HOLE, but has indicated they will be more forthcoming this week on Nov. 3, 2009 at a conference for investors and analysts at the Company's World Headquarters For Sustainable Excellence in Wilmington, Delaware. Heads-up, fellow investors!

funfundvierzig...funfun..